MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the composition of its Board of Directors following the completion of the company's separation from Medtronic. This new Board composition reflects MiniMed's priorities as an independent public company, including focused growth, continued innovation, disciplined execution and broader access to diabetes technology. The Board's collective experience spans healthcare delivery and access, medical technology, manufacturing operations, corporate governance and consumer engagement.

Kevin E. Lofton remains as chair of the Board. Amy Bricker and Tim L. Main are joining the Board, effective immediately, as part of the planned transition from Medtronic-designated directors. Their appointments complete MiniMed's transition to its post-separation Board.

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.